All studies
Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional
A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic Malignancies
At a glance
Status
Ongoing, recruiting
Phase
Human Pharmacology (Phase I)- Other
Sponsor
Prelude Therapeutics Inc.
Enrolment target
109
Start
14 Sep 2023
Richter's SyndromeChronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma (MCL)Acute myeloid leukemia (AML)Marginal zone lymphoma (MZL)T-cell lymphoma (TCL) subtypesMyelodysplastic syndrome (MDS)MDS/myeloproliferative neoplasm (MPN) overlap syndromeChronic myelomonocytic leukemia (CMML)Small Lymphocytic Lymphoma (SLL)Aggressive B-Cell Non-Hodgkin's Lymphoma
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (4)
- —Germany
- —Poland
- —Italy
- —France
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.